Honestly a big reason Nader had to go was because he was becoming more and more of a liability by increasingly attracting negative attention from the acronyms.

Thankfully the separation has been made and with Tanya Durkee Urbach on the Board, I am confident that public statements going forward will comport with what's expected from regulators. Adding a more professional culture to a potential blockbuster drug is a winning formula going forward.